Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486416 | 0.85 | GPR119 (0.59) | GPR119 | |
| SCHEMBL3486727 | 0.83 | PSMB5 (0.33) | GPR119OPRK1TSHRGRIN2B | |
| SCHEMBL10316354 | 0.77 | ITGB3 (0.54) | L3MBTL3GPR119FFAR4 | |
| SCHEMBL13506681 | 0.76 | GRM4 (0.51) | HSD17B10ALDH1A1TSHR | |
| SCHEMBL3485750 | 0.75 | GPR119 (0.47) | L3MBTL3GPR119FFAR4 | |
| SCHEMBL10316358 | 0.75 | ITGB3 (0.49) | L3MBTL3GPR119FFAR4ALDH1A1 | |
| SCHEMBL10316360 | 0.74 | ITGB3 (0.52) | GPR119ALDH1A1 | |
| SCHEMBL13506302 | 0.73 | L3MBTL3 (0.47) | L3MBTL3GPR119FFAR4ALDH1A1 | |
| SCHEMBL1582298 | 0.72 | CHRM5 (0.41) | TSHRGRIN2B | |
| SCHEMBL13506075 | 0.72 | ITGB3 (0.47) | GPR119ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029688-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| EP-2121661-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008085316-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029688-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR139, GPR27 | L3MBTL3 4837/4885HSD17B10 1629/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.